Published in Invest Ophthalmol Vis Sci on March 05, 2009
Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait. Nat Rev Genet (2010) 3.20
Mechanisms of age-related macular degeneration. Neuron (2012) 2.62
Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood (2010) 2.08
Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood (2011) 1.82
Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol (2010) 1.68
Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction. Invest Ophthalmol Vis Sci (2014) 1.55
Age-related macular degeneration in the aspect of chronic low-grade inflammation (pathophysiological parainflammation). Mediators Inflamm (2014) 1.20
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci (2010) 1.17
Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration. Br J Pharmacol (2011) 1.16
The role of the immune response in age-related macular degeneration. Int J Inflam (2013) 1.16
Intrinsic depot-specific differences in the secretome of adipose tissue, preadipocytes, and adipose tissue-derived microvascular endothelial cells. Diabetes (2010) 1.13
The membrane attack complex in aging human choriocapillaris: relationship to macular degeneration and choroidal thinning. Am J Pathol (2014) 1.12
Localization of complement 1 inhibitor (C1INH/SERPING1) in human eyes with age-related macular degeneration. Exp Eye Res (2009) 0.99
Sublytic membrane-attack-complex (MAC) activation alters regulated rather than constitutive vascular endothelial growth factor (VEGF) secretion in retinal pigment epithelium monolayers. J Biol Chem (2011) 0.99
The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization. Mol Immunol (2011) 0.98
Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization. J Ocul Pharmacol Ther (2012) 0.96
Relationship between complement membrane attack complex, chemokine (C-C motif) ligand 2 (CCL2) and vascular endothelial growth factor in mouse model of laser-induced choroidal neovascularization. J Biol Chem (2011) 0.96
Pathological consequences of long-term mitochondrial oxidative stress in the mouse retinal pigment epithelium. Exp Eye Res (2012) 0.95
Role of ocular complement factor H in a murine model of choroidal neovascularization. Am J Pathol (2010) 0.95
Mitochondrial oxidative stress in the retinal pigment epithelium leads to localized retinal degeneration. Invest Ophthalmol Vis Sci (2014) 0.95
CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res (2011) 0.94
Genome-wide association studies of schizophrenia: does bigger lead to better results? Curr Opin Psychiatry (2012) 0.94
Detection of complement activation using monoclonal antibodies against C3d. J Clin Invest (2013) 0.93
Oxidative stress sensitizes retinal pigmented epithelial (RPE) cells to complement-mediated injury in a natural antibody-, lectin pathway-, and phospholipid epitope-dependent manner. J Biol Chem (2013) 0.92
Matrix metalloproteinase activity creates pro-angiogenic environment in primary human retinal pigment epithelial cells exposed to complement. Invest Ophthalmol Vis Sci (2012) 0.92
Stroke genetics: prospects for personalized medicine. BMC Med (2012) 0.90
Alternative complement pathway deficiency ameliorates chronic smoke-induced functional and morphological ocular injury. PLoS One (2013) 0.88
Unravelling the genetics of ischaemic stroke. PLoS Med (2010) 0.87
Improvement and optimization of standards for a preclinical animal test model of laser induced choroidal neovascularization. PLoS One (2014) 0.86
Selective accumulation of the complement membrane attack complex in aging choriocapillaris. Exp Eye Res (2015) 0.85
Polyethylene glycol (PEG)-induced mouse model of choroidal neovascularization. J Biol Chem (2011) 0.85
Local production of the alternative pathway component factor B is sufficient to promote laser-induced choroidal neovascularization. Invest Ophthalmol Vis Sci (2015) 0.81
Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE. Neurosci Lett (2012) 0.81
Molecular response of chorioretinal endothelial cells to complement injury: implications for macular degeneration. J Pathol (2015) 0.81
Connecting the innate and adaptive immune responses in mouse choroidal neovascularization via the anaphylatoxin C5a and γδT-cells. Sci Rep (2016) 0.80
Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy. J Am Soc Nephrol (2015) 0.80
Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis. Sci Rep (2015) 0.78
Is asthma related to choroidal neovascularization? PLoS One (2012) 0.78
Age-Related Macular Degeneration: A Disease of Systemic or Local Complement Dysregulation? J Clin Med (2014) 0.78
Complement activation in the context of stem cells and tissue repair. World J Stem Cells (2015) 0.78
New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities. Semin Immunol (2016) 0.78
Targeting inflammation in emerging therapies for genetic retinal disease. Int J Inflam (2013) 0.77
Phosphatidylserine (PS) Is Exposed in Choroidal Neovascular Endothelium: PS-Targeting Antibodies Inhibit Choroidal Angiogenesis In Vivo and Ex Vivo. Invest Ophthalmol Vis Sci (2015) 0.77
The effect of triamcinolone acetonide on laser-induced choroidal neovascularization in mice using a hypoxia visualization bio-imaging probe. Sci Rep (2015) 0.77
T-helper-associated cytokines expression by peripheral blood mononuclear cells in patients with polypoidal choroidal vasculopathy and age-related macular degeneration. BMC Ophthalmol (2016) 0.76
Preliminary in vitro and in vivo assessment of a new targeted inhibitor for choroidal neovascularization in age-related macular degeneration. Drug Des Devel Ther (2016) 0.75
Intravitreal inhibition of complement C5a reduces choroidal neovascularization in mice. Graefes Arch Clin Exp Ophthalmol (2015) 0.75
A Targeted Inhibitor of the Alternative Complement Pathway Accelerates Recovery From Smoke-Induced Ocular Injury. Invest Ophthalmol Vis Sci (2016) 0.75
Complement factors C1q, C3 and C5b-9 in the posterior sclera of guinea pigs with negative lens-defocused myopia. Int J Ophthalmol (2015) 0.75
Electrostatic Steering Accelerates C3d:CR2 Association. J Phys Chem B (2016) 0.75
New Insights on Complement Inhibitor CD59 in Mouse Laser-Induced Choroidal Neovascularization: Mislocalization After Injury and Targeted Delivery for Protein Replacement. J Ocul Pharmacol Ther (2017) 0.75
Complement factor H polymorphism in age-related macular degeneration. Science (2005) 31.10
Complement factor H variant increases the risk of age-related macular degeneration. Science (2005) 17.95
Complement factor H polymorphism and age-related macular degeneration. Science (2005) 17.79
A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A (2005) 13.44
An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res (2001) 8.38
Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet (2006) 8.33
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature (2008) 7.10
Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med (2007) 6.47
CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration. Nat Genet (2006) 4.51
Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A (2006) 3.25
Multiple, parallel cellular suicide mechanisms participate in photoreceptor cell death. Exp Eye Res (2006) 2.26
Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol (2008) 2.19
Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA (2006) 2.15
Structural basis for complement factor H linked age-related macular degeneration. J Exp Med (2007) 2.02
Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest (2008) 1.94
Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol (2005) 1.89
His-384 allotypic variant of factor H associated with age-related macular degeneration has different heparin binding properties from the non-disease-associated form. J Biol Chem (2006) 1.79
Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest (2005) 1.70
A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol (2008) 1.70
Complement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction. Proc Natl Acad Sci U S A (2007) 1.62
Structure-function analysis of rods and cones in juvenile, adult, and aged C57bl/6 and Balb/c mice. Vis Neurosci (2003) 1.55
Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest (2003) 1.46
Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H. J Immunol (2006) 1.42
Role of neurotrophin receptor TrkB in the maturation of rod photoreceptors and establishment of synaptic transmission to the inner retina. J Neurosci (1999) 1.34
A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. J Immunol (1990) 1.32
CD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degeneration. J Immunol (2007) 1.31
Eliminating complement factor D reduces photoreceptor susceptibility to light-induced damage. Invest Ophthalmol Vis Sci (2007) 1.30
Age as an independent risk factor for severity of experimental choroidal neovascularization. Invest Ophthalmol Vis Sci (2002) 1.23
Electroretinography in the prognosis and classification of central retinal vein occlusion. Arch Ophthalmol (1983) 1.20
Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization. J Cell Physiol (2004) 1.19
Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration. Proc Natl Acad Sci U S A (2003) 1.17
Complement factor H binds to denatured rather than to native pentameric C-reactive protein. J Biol Chem (2008) 1.15
Neovascularization in central retinal vein occlusion: electroretinographic findings. Arch Ophthalmol (1988) 1.12
Functional and structural implications of the complement factor H Y402H polymorphism associated with age-related macular degeneration. Invest Ophthalmol Vis Sci (2008) 1.12
Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol (2008) 1.07
Photoreceptor synapses degenerate early in experimental choroidal neovascularization. J Comp Neurol (2005) 1.02
Differences in the temporal expression of regulatory growth factors during choroidal neovascular development. Exp Eye Res (2008) 0.94
Long-term ERG analysis in the partially light-damaged mouse retina reveals regressive and compensatory changes. Vis Neurosci (2006) 0.87
Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet (2008) 12.51
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med (2005) 6.83
High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology (2010) 4.11
A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat Genet (2008) 3.71
Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis (2010) 2.64
Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet (2011) 2.54
Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci U S A (2009) 2.31
Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest (2003) 2.26
Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev (2005) 2.25
The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture. Arthritis Rheum (2008) 2.13
Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum (2010) 1.98
Common variants within MECP2 confer risk of systemic lupus erythematosus. PLoS One (2008) 1.98
Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol (2003) 1.89
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Noncanonical autophagy promotes the visual cycle. Cell (2013) 1.74
A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. FASEB J (2008) 1.71
Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest (2005) 1.70
A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol (2008) 1.70
Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype. Arthritis Rheum (2005) 1.58
Human retinal pigment epithelium cells as functional models for the RPE in vivo. Invest Ophthalmol Vis Sci (2011) 1.55
Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant (2013) 1.53
Estrogen receptor alpha modulates Toll-like receptor signaling in murine lupus. Clin Immunol (2012) 1.53
Complement function in mAb-mediated cancer immunotherapy. Trends Immunol (2004) 1.52
Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet (2011) 1.49
Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest (2003) 1.46
Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury. J Biol Chem (2009) 1.45
A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood (2012) 1.45
Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis Rheum (2009) 1.43
Identification of a systemic lupus erythematosus susceptibility locus at 11p13 between PDHX and CD44 in a multiethnic study. Am J Hum Genet (2010) 1.43
The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus. PLoS One (2010) 1.42
Lifetime exposure to trichloroethylene (TCE) does not accelerate autoimmune disease in MRL +/+ mice. J Environ Sci Health A Tox Hazard Subst Environ Eng (2008) 1.42
Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis (2011) 1.41
Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am J Hum Genet (2012) 1.41
Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol (2004) 1.40
IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis (2011) 1.38
Role for Msh5 in the regulation of Ig class switch recombination. Proc Natl Acad Sci U S A (2007) 1.35
The mammalian cone visual cycle promotes rapid M/L-cone pigment regeneration independently of the interphotoreceptor retinoid-binding protein. J Neurosci (2011) 1.33
Osteopontin and systemic lupus erythematosus association: a probable gene-gender interaction. PLoS One (2008) 1.31
Occupational risk factors for the development of systemic lupus erythematosus. J Rheumatol (2004) 1.31
Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther (2011) 1.31
Eliminating complement factor D reduces photoreceptor susceptibility to light-induced damage. Invest Ophthalmol Vis Sci (2007) 1.30
Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States. Arthritis Rheum (2002) 1.29
Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients. Ann Rheum Dis (2010) 1.26
Autoantibody prevalence and lupus characteristics in a unique African American population. Arthritis Rheum (2008) 1.25
Effects of active and inactive phospholipase D2 on signal transduction, adhesion, migration, invasion, and metastasis in EL4 lymphoma cells. Mol Pharmacol (2008) 1.23
A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum (2009) 1.23
A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J Clin Invest (2009) 1.21
The lupus family registry and repository. Rheumatology (Oxford) (2010) 1.21
Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study. Arthritis Rheum (2011) 1.19
Essential roles of grp94 in gut homeostasis via chaperoning canonical Wnt pathway. Proc Natl Acad Sci U S A (2013) 1.19
Comparison of autoantibody specificities between traditional and bead-based assays in a large, diverse collection of patients with systemic lupus erythematosus and family members. Arthritis Rheum (2012) 1.19
Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am J Pathol (2006) 1.17
The transcription factor Fli-1 modulates marginal zone and follicular B cell development in mice. J Immunol (2008) 1.16
Genetic sphingosine kinase 1 deficiency significantly decreases synovial inflammation and joint erosions in murine TNF-alpha-induced arthritis. J Immunol (2010) 1.16
Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res (2005) 1.16
Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int (2004) 1.15
Admixture mapping in lupus identifies multiple functional variants within IFIH1 associated with apoptosis, inflammation, and autoantibody production. PLoS Genet (2013) 1.14
Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells. Arthritis Rheum (2006) 1.14
Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study. Arthritis Rheum (2002) 1.14
Mapping the intermedilysin-human CD59 receptor interface reveals a deep correspondence with the binding site on CD59 for complement binding proteins C8alpha and C9. J Biol Chem (2011) 1.12
Suppression of humoral immunity in mice following exposure to perfluorooctane sulfonate. Toxicol Sci (2008) 1.12
The phytoalexin resveratrol regulates the initiation of hypersensitive cell death in Vitis cell. PLoS One (2011) 1.12
High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups. Arthritis Rheum (2009) 1.11
Crystal structure of CD59: implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attack complex. Acta Crystallogr D Biol Crystallogr (2007) 1.11
A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol (2007) 1.10
Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history. J Clin Epidemiol (2002) 1.10
Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J Immunol (2009) 1.09
Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol (2006) 1.09
Defining the CD59-C9 binding interaction. J Biol Chem (2006) 1.09
The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy. Am J Physiol Renal Physiol (2007) 1.08
Sociodemographic associations with early disease damage in patients with systemic lupus erythematosus. Arthritis Rheum (2007) 1.08
The role of genetic variation near interferon-kappa in systemic lupus erythematosus. J Biomed Biotechnol (2010) 1.07
Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol (2008) 1.07
Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups. Ann Rheum Dis (2012) 1.07
Absence of functional alternative complement pathway alleviates lupus cerebritis. Eur J Immunol (2007) 1.06
Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: mortality risk and quality of life early in the course of disease. Arthritis Rheum (2008) 1.06
Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus. Ann Rheum Dis (2011) 1.06
Inhibition of beta-adrenergic receptor trafficking in adult cardiocytes by MAP4 decoration of microtubules. Am J Physiol Heart Circ Physiol (2004) 1.06
Association of serum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis. Arthritis Rheum (2008) 1.05
Age-related changes in plasma coenzyme Q10 concentrations and redox state in apparently healthy children and adults. Clin Chim Acta (2004) 1.05
The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J Autoimmun (2008) 1.04
Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int (2010) 1.04
The alternative complement pathway propagates inflammation and injury in murine ischemic stroke. J Immunol (2012) 1.03
Impact of estrogen receptor deficiency on disease expression in the NZM2410 lupus prone mouse. Clin Immunol (2008) 1.03
Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice. J Immunol (2011) 1.02
RNA-Seq analysis of Cocos nucifera: transcriptome sequencing and de novo assembly for subsequent functional genomics approaches. PLoS One (2013) 1.02
CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv Exp Med Biol (2013) 1.01
Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephrotic syndrome and demonstrate a key role for C5b-9. J Immunol (2005) 1.01